Palifermin ( DrugBank: Palifermin )

5 diseases

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01712945 (ClinicalTrials.gov)	June 2012	19/10/2012	Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis ...	Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemt ...	Multiple Sclerosis	Drug: Palifermin;Drug: Alemtuzumab	Cambridge University Hospitals NHS Foundation Trust	NULL	Terminated	18 Months	50 Years	All	40	Phase 1/Phase 2	United Kingdom
2	EUCTR2011-005606-30-GB (EUCTR)	25/04/2012	02/04/2012	Preventing patients with multiple sclerosis from developing side effects following treatment with al ...	Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemt ...	This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patie ...	Trade Name: Kepivance Product Name: Kepivance INN or Proposed INN: Palifermin Trade Name: MabCampath Pro ...	Cambridge University Hospitals NHS Foundation Trust and University of Cambridge	NULL	Not Recruiting			Female: yes Male: yes	86	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom

臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00881556 (ClinicalTrials.gov)	August 20, 2009	14/4/2009	Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)	A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLO ...	Epidermolysis Bullosa	Drug: Palifermin;Drug: Fludarabine;Drug: Busulfan;Drug: Lorazepam;Drug: Alemtuzumab;Drug: Tacrolimus ...	Columbia University	NULL	Terminated	N/A	21 Years	All	3	Early Phase 1	United States

臨床試験数 : 17 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 101

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02037347 (ClinicalTrials.gov)	October 2010	13/1/2014	Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis	Palifermin Treatment of Toxic Epidermal Necrolysis	Toxic Epidermal Necrolysis;Stevens-Johnson Syndrome	Drug: Palifermin	Brett King	Swedish Orphan Biovitrum	Terminated	18 Years	N/A	All	1	Phase 1/Phase 2	United States

臨床試験数 : 13 / 薬物数 : 19 - (DrugBank : 8) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02037347 (ClinicalTrials.gov)	October 2010	13/1/2014	Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis	Palifermin Treatment of Toxic Epidermal Necrolysis	Toxic Epidermal Necrolysis;Stevens-Johnson Syndrome	Drug: Palifermin	Brett King	Swedish Orphan Biovitrum	Terminated	18 Years	N/A	All	1	Phase 1/Phase 2	United States

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01306019 (ClinicalTrials.gov)	September 25, 2012	26/2/2011	Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe ...	Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Co ...	X-linked Severe Combined Immunodeficiency (XSCID)	Drug: Palifermin;Drug: Busulfan;Biological: Ex vivo culture and transduction of the patient's autolo ...	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Suspended	2 Years	40 Years	Male	19	Phase 1/Phase 2	United States
2	NCT03315078 (ClinicalTrials.gov)	April 2012	16/10/2017	Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Co ...	Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Co ...	X-Linked Combined Immunodeficiency Diseases	Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT ...	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	2 Years	40 Years	All	13	Phase 1/Phase 2	United States